

Table 2. Results of the treatment with somatostatin analogs before or after pituitary surgery in patients with acromegaly

	SSA before surgery N = 11	SSA after surgery N = 62	p
Random serum GH $\mu\text{g/L}$, median [range]	12.10 [0.46 – 71.1]	2.0 [0.1 – 64.0]	<0.05
Serum IGF-1 \times ULN, median [range]	2.30 [1.5 – 4.8]	0.49 [0.4 – 4.1]	<0.001
Random serum GH ≤ 2.5 $\mu\text{g/L}$, no. (%)	3 / 11 (27.2%)	36 / 62 (58.0%)	<0.05
Any serum GH ≤ 1 $\mu\text{g/L}$, no. (%)	1 / 11 (9%)	29 / 62 (46.7%)	<0.05
Normal serum IGF-1, no. (%)	0	22 / 61 (36.0%)	<0.05
Controlled patients, no. (%)	0	18 / 61 (29.5%)	0.06
Optimally controlled patients, no. (%)	0	19 / 61 (31.1%)	<0.05

Legend: Controlled patients = random serum GH ≤ 2.5 $\mu\text{g/L}$ and normal IGF-1 for age; optimally controlled patients = any serum GH ≤ 1 $\mu\text{g/L}$ and normal IGF-1 for age; no.: number; SSA: somatostatin analogs.